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Abstract
Objectives Fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET-CT) is typically considered
to have minimal yield in gastric cancer, and so is not consistently recommended by international guidelines. However, its yield is
considerable in esophageal and junctional cancer, identifying unsuspected metastases and risk-stratifying patients using meta-
bolic nodal stage (mN). We aimed to determine the contemporary utility of routine 18F-FDG PET-CT in gastric cancer.
Methods We routinely stage patients with non-junctional gastric cancer with PET-CT, provided initial CT does not demonstrate
unequivocal metastases. We performed a retrospective study of all such patients staged in our institution from January 2007 to
July 2016. Our primary endpoint was detection of incurable disease. Our secondary endpoint was disease-free survival following
gastrectomy. Decision theory, economic, and predictive models were generated.
Results The primary tumor was FDG-avid in 225/279 patients (80.6%). Seventy-two (25.8%) had FDG-avid nodes (resectable
by D2 lymphadenectomy). This was not influenced by the Lauren classification. Unsuspected metastases were identified in 20
patients (7.2%). In 13 (4.7%), these would not have been otherwise identified. Decision theory and economicmodeling supported
routine PET-CT. Patients with FDG-avid nodes were more likely to have incurable disease (51.4% versus 15.5%; p < 0.001), and
a worse prognosis if not: multivariate hazard ratio 2.19 (1.23–3.91; p = 0.008). Prognosis worsened with mN stage.
Conclusions PET-CT appears useful when used routinely for non-junctional gastric cancer, and should be considered in inter-
national recommendations. Any extra costs appear small and offset by avoiding futile investigations and radical treatment. mN
stage identifies patients at risk of early recurrence and death.
Key Points
• PET-CT is typically not considered useful when staging gastric cancer. We describe a retrospective study of 279 patients
routinely staged with PET-CT in the absence of metastases on CT.
• The primary tumor was avid in 80% of patients. Twenty-five percent had resectable avid nodes. PET-CT identified previously
unsuspected metastases in 7% of patients, which would likely not have been identified by conventional staging without PET-CT
in 5%. These patients were much more likely to have avid nodes.
• Beyond avoiding futile investigations and radical treatment in this 5%, we found patients with FDG-avid nodes (metabolic
nodal stage, mN) to have a worse disease-free survival after gastrectomy.
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mN Metabolic nodal stage
mNR Metabolic nodal response
MRI Magnetic resonance imaging
NAC Neoadjuvant chemotherapy
NHS National Health Service
NPV Negative predictive value
OR Odds ratio
OS Overall survival
OSEM Ordered subset expectation maximization
PET Positron emission tomography
PPV Positive predictive value
SUVmax Maximum standardized uptake variable
Introduction
The contemporary utility of 18F-fluorodeoxyglucose (FDG)
positron emission tomography–computed tomography (PET-
CT) in gastric cancer is unclear. While in esophageal and
gastro-esophageal junctional (GOJ) cancer it has clear utility
in identifying metastases [1, 2], experience in gastric cancer is
limited to two small studies of locally advanced disease from
Korea and America. This lack of experience is perhaps due to
initial reports that gastric cancer (particularly the diffuse sub-
type) is frequently not avid [3]. PET-CT is therefore not rec-
ommended routinely in Europe [3, 4].
We recently reported a novel aspect of PET-CT’s utility in
esophageal and GOJ cancer: metabolic nodal stage (mN). We
found that patients with FDG-avid nodes within a standard
lymphadenectomy field had a higher risk of disease progres-
sion before surgery and recurrence and death afterwards [5–7].
However, whether this is true in gastric cancer is unclear,
previously assessed by just two studies of Korean and
Chinese populations [8, 9].
Radical treatment risks death and complications, and de-
spite ostensibly curative surgery, recurrence remains common
[10]. There is therefore an urgent need to improve staging to
prevent futile treatment and develop prognostic markers. We
have routinely staged patients with esophageal and gastric
cancer with PET-CT for 10 years in the absence of unequivo-
cal metastases on CT and conducted the largest retrospective
study to date to determine its utility in a Western population.
Materials and methods
Study design and ethical approval
We included all patients with non-GOJ gastric adenocarcino-
ma without unequivocal metastases on CT from January 2007
to July 2016, following institutional Research and
Development committee approval.
Staging
All examinations were reported and reviewed at multidisci-
plinary team (MDT) meetings by specialist gastrointestinal
radiologists, using the contemporary TNM 6th [11] or 7th
[12] editions. PET-CT examinations were dual reported inde-
pendently by two dedicated high-volume PET-CT radiolo-
gists, trained in nuclear medicine and clinical radiology.
Patients were staged initially with a contrast-enhanced multi-
detector CT chest abdomen and pelvis as previously reported
[13], followed by PET-CT and laparoscopy for disease more
advanced than Tx/T1. Endoscopic ultrasound (EUS) was per-
formed selectively.
PET-CTwas performed before November 2009 using a GE
Discovery STE 16-slice (60 min post 400 MBq 18F-FDG);
after November 2009, a GE Discovery 690 64-slice system
then also a GE Discovery 710 from September 2014, (both
90 min post 4 MBq/Kg FDG) all using ordered subset expec-
tation maximization (OSEM) reconstruction, from skull base
to upper thighs at 4 min per bed; after November 2014, a
Bayesian penalized likelihood (BPL) reconstruction technique
was used (Q.Clear) without intravenous contrast.
Data
The following data were collected: patient gender and age;
tumor location, grade of differentiation [12] and Lauren classi-
fication [14]; contemporaneous TNM stage; tumor maximum
standardized uptake value (SUVmax) with that above back-
ground mediastinal blood pool being positive, the presence
and number of FDG-avid nodes (mM1 1–2 nodes, mN2 > 2),
defined as areas of avidity within a CT correlate suggesting a
node visible separately from the primary tumor, within standard
lymphadenectomy fields [13]; treatment strategy and neoadju-
vant chemotherapy (NAC) regimen; restaging results after
NAC; pathological stage [12], and response to NAC
(Mandard Tumor Regression Grade 1–3 being response [15]);
and recurrence and death (censored on 1st September 2017) .
Clinical T stage was grouped pragmatically as x/1, 2/3, or 4
according to the TNM 7th edition, and N as 0 or 1 to allow
synthesis of data spanning the 6th and 7th editions (which had
major differences in classification). Where available, EUS
was used. Pathological stage was converted to TNM 7.
Metastatic disease was defined as that outside a standard
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resection and D2 lymphadenectomy field, or invasion into
unresectable structures. Metastatic disease evidenced on
PET-CT was defined as such an area of avidity with a robust
structural correlate. Suspicious isolated foci of avidity without
a correlate were further investigated with cross-sectional im-
aging, direct visualization, or histopathology. Metastatic dis-
ease on imaging was subject to MDT consensus,
unresectability at surgery by frozen section or consensus of
two consultant esophagogastric surgeons.
Neoadjuvant chemotherapy and restaging
Patients received 3 or 4 cycles of pre- +/− post-operative
epirubicin, cisplatin, and 5-fluorouracil (ECF); epirubicin, cis-
platin, and capecitabine (ECX); or epirubicin, oxaliplatin, and
5-fluorouracil ± bevacizumab as previously described, de-
pending on contemporaneous practice and trials [5]. Patients
were restaged with CT or PET-CT depending on local avail-
ability or trial protocols.
Surgery
Total/subtotal gastrectomy was performed open or
laparoscopically with D2 lymphadenectomy.
Follow-up
Patients were reviewed clinically at 2 and 6 weeks after sur-
gery, 3 monthly to one year, and 6–12monthly thereafter for at
least 5 years. Investigations for recurrence were performed
only when suspected, typically involving cross-sectional im-
aging with CT or PET-CT ± endoscopy.
Statistical analysis
Analyses were performed using R v3.0.2 [16]. Groups
were compared using Fisher’s exact test and non-
parametric data using the Mann-Whitney U test. p values
were corrected using the Bonferroni technique for group
and univariate analysis [17]. Multivariate binary logistic
and Cox regression were performed for variables with
p < 0.1, having excluded perfect separators. Logistic re-
gression and recursive partitioning models were generat-
ed as previously described [2]. Survival metrics were
calculated using the Kaplan-Meier method, follow-up
using the reverse Kaplan-Meier method.
Probability thresholds were generated as previously de-
scribed [2, 18], using metrics from this study or from the
literature if unavailable: false positive rate 0.22% (risk of in-
vestigation of false positives assumed to be minimal for fine
needle aspiration [19] and 0.47% for mediastinoscopy [20]),
sensitivity 49.3%, 90-day mortality of surgery 1.66%, 2-year
survival 52.4%, and lifetime attributable cancer risk from
13-mSv radiation dose 0.067% [21].
An economic model was developed using 2017 UK
National Health Service (NHS) tariffs for laparoscopy
(£735), 3 cycles ECX (£8004), gastrectomy (£10,402), PET-
CT (£980), liver MRI (£145), mediastinoscopy (£1432), and
ultrasound-guided fine needle aspiration (£599). A 37.6%
likelihood of NAC and consequent restaging PET-CT was
assumed.
Results
Two hundred seventy-nine consecutive patients were identi-
fied (Table 1). EUS was performed in 61 (21.9%), laparosco-
py in 220 (79.9%).
Table 1 Patient and tumor characteristics
Patients Total 279
Age (median) 71.0 (IQR 62.3–78.0)
Gender
Male (%) 185 (66.3)
Female (%) 94 (32.7)
Tumor
Cell type
Intestinal (%) 138 (49.5)
Diffuse (%) 86 (30.8)
Mixed (%) 26 (9.32)
Unknown (%) 29 (10.4)
Grade of differentiation
Well (%) 13 (4.66)
Moderate (%) 61 (29.9)
Poor (%) 195 (69.9)
Unknown (%) 10 (2.58)
Site
Proximal (%) 66 (23.7)
Body (%) 65 (23.3)
Distal (%) 134 (48.0)
Linitis (%) 14 (5.02)
Staging
T stage
x/1 (%) 57 (20.4)
2–3 (%) 165 (59.1)
4 (%) 54 (19.4)
Unknown (%) 3 (1.08)
N stage
0 (%) 130 (46.6)
≥ 1 (%) 136 (48.7)
Unknown (%) 3 (1.08)
IQR, interquartile range
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Tumor avidity
The primary tumor was FDG-avid in 225 cases (80.6%).
Seventy-two (25.8%) had FDG-avid nodes. An avid tumor
was more likely with advancing T stage: T2–3 multivariate
OR 3.38 (2.28–5.02; p = 0.002) and T4 7.46 (3.38–14.7; p =
0.003). There were no associations with the Lauren classifica-
tion or differentiation (supplementary Table 1). Specifically,
61/86 (70.9%) of diffuse tumors were avid, although less so
than intestinal: median SUVmax 5.10 (IQR 2.50–8.10) versus
8.90 (5.05–15.4; p < 0.001). There were no associations with
nodal avidity or PET-CT system/reconstruction technique
(supplementary Tables 1–2).
Metastases on PET-CT
PET-CT identified possible or unequivocal metastatic disease
in 40 patients (14.3%). In 14 (5.02%), this confirmed those
suspected on prior CT. In 26 (9.32%), this was unsuspected.
Of these 26, PET-CT was unequivocal in 12 (4.30%) and
indeterminate in 14. These 14 were investigated further, with
metastases confirmed in 8 (2.87%; n = 7 laparoscopy, n = 1
fine needle aspiration) and refuted in 6 (2.15%; n = 4 laparos-
copy, n = 1 liver MRI, n = 1 mediastinoscopy). In a further 5
(1.79%), PET-CT refuted metastases suggested by CT.
In total, PET-CT identified unsuspected metastases in 20
patients (7.17%): n = 5 peritoneal, n = 2 peritoneal + liver/nod-
al, n = 5 liver, n = 1 liver + nodal, n = 6 nodal, and n = 1 nodal +
skeletal. In 13 of these 20 (4.66%), these metastases would not
have been visible at subsequent laparoscopy (for example ret-
roperitoneal/mediastinal/cervical nodes, skeletal, or deep liver
metastases). In patients without metastatic disease on PET-CT,
this was subsequently identified in 35 (false negatives; 12.5%;
n = 34 at laparoscopy, n = 1 at surgery without NAC).
Following complete staging, there were 34 true positives
(evident on PET-CT, either unequivocal or subsequently con-
firmed), 6 false positives (possible metastases subsequently
refuted), 35 false negatives (identified following PET-CT),
and 204 true negatives (no metastatic disease following stag-
ing or surgery without NAC). PET-CT was 49.3% sensitive
(37.0–61.6) and 97.1% specific (93.9–98.9) for metastatic dis-
ease. Positive predictive value (PPV) was 85.0% (71.3–
92.8%); negative predictive value (NPV) was 85.4% (82.2–
88.1%).
Factors associated with metastases on PET-CT
Of factors available before PET-CT, both advancing T and N
stage were associated with true positive metastases on PET-
CT (supplementary Table 3). Only N ≥ 1 stage remained sig-
nificant on multivariate analysis (Table 2). When PET-CT
factors were considered, only the presence of FDG-avid nodes
was predictive: multivariate OR 3.97 (1.33–11.9; p = 0.014).
This was independent of clinical N ≥ 1 stage, which was bor-
derline significant (Table 2).
Table 2 Multivariate regression: factors associated with metastases
Characteristic Odds ratio (95% CI) p
Metastases on PET-CT: pre-PET-CT variables
Age 0.99 (0.95–1.03) 0.599
Gender
Female Reference Reference
Male 0.59 (0.22–1.59) 0.297
Tumor site
Proximal Reference Reference
Body 0.77 (0.23–2.60) 0.669
Distal 0.64 (0.21–1.96) 0.438
Linitis 0.80 (0.07–8.58) 0.854
Lauren classification
Intestinal Reference Reference
Diffuse 1.94 (0.67–5.67) 0.224
T stage
x/1 Reference Reference
2/3 0.57 (0.13–2.51) 0.454
4 1.97 (0.42–9.31) 0.393
N stage
0 Reference Reference
≥ 1 5.86 (1.67–20.6) 0.006
Metastases on PET-CT: all variables
Age 1.00 (0.95–1.04) 0.926
Gender
Female Reference Reference
Male 0.55 (0.19–1.55) 0.260
Tumor site
Proximal Reference Reference
Body 1.05 (0.28–3.88) 0.945
Distal 0.62 (0.19–2.06) 0.438
Linitis 1.22 (0.09–15.9) 0.881
Lauren classification
Intestinal Reference Reference
Diffuse 1.19 (0.37–2.81) 0.764
T stage
x/1 Reference Reference
2/3 0.43 (0.09–2.06) 0.293
4 1.56 (0.30–8.14) 0.599
N stage
0 Reference Reference
≥ 1 3.78 (0.96–15.0) 0.058
mN
0 Reference Reference
≥ 1 3.97 (1.33–11.9) 0.014
SUVmax 1.04 (0.99–1.10) 0.148
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Twenty-two of 72 (30.6%) patients with FDG-avid
nodes had metastatic disease on PET-CT, compared with
12/207 (5.80%) without (p < 0.001). This association
persisted for ≥ 2 avid nodes (mN2 stage; multivariate OR
7.11 [3.84–13.2] p = 0.001) rather than ≤ 2 (mN1 stage; OR
0.96 [0.38–2.41] p = 0.956); 18 of 45 (40.0%) versus 4 of
27 (14.8%), respectively (p < 0.001).
Factors associated with metastases at staging overall
Overall, metastases were more likely with worsening differ-
entiation, T and N stage, tumor site (linitis and proximal tu-
mors), and the presence of FDG-avid nodes (supplementary
Table 3). On multivariate analysis, only FDG-avid nodes
remained significant (Table 3).
Thirty-seven of 72 (51.4%) patients with FDG-avid nodes
had metastases, compared with 32/207 (15.5%) without
(p < 0.001). Again, risk was most for patients with mN stage
2: 28/45 (62.2%) versus 9/27 with mN1 (33.3%; p < 0.0001).
Indeed, on multivariate analysis, just mN2 stage remained
significant: OR 6.15 (2.26–16.8; p < 0.001).
Factors associated with unsuspected metastases
at laparoscopy/surgery without chemotherapy
Almost identical associations were seen for unsuspected me-
tastases at surgery (i.e., false negatives on PET-CT; supple-
mentary Table 4). On multivariate analysis, only FDG-avid
nodes persisted (Table 3).
Fifteen of 45 (33.3%) patients with FDG-avid nodes on
PET-CT (but no apparent metastases) had unsuspected metas-
tases compared with 20/195 without (10.3%; p = 0.001). Risk
increased with mN stage: mN1 OR 4.49 (1.03–19.5; p =
0.045) and mN2 OR 6.03 (1.38–26.3; p = 0.017).
Decision theory
The probability threshold for PET-CTwas 1.90%, i.e., the pre-
PET-CT probability of finding metastases at which its risk
(radiation and the implications of false positives and false
negatives) justifies its potential benefit [2]. No models could
identify patients below this to forgo PET-CT.
Economic model
An economic model was developed to calculate net stag-
ing costs, assuming PET-CT identified unsuspected me-
tastases in 7 of 279 patients which might have been
identified at laparoscopy, plus 13 in whom these would
not. This would save 9 staging laparoscopies (as in 11
cases, laparoscopy was performed to confirm/refute find-
ings), plus 13 futile attempts at treatment (NAC,
restaging plus gastrectomy). Possible metastases resulted
in one additional liver MRI, mediastinoscopy, and percu-
taneous FNA. The net additional cost was £322.01 per
patient, and £6910.86 to avoid one futile attempt at rad-
ical treatment.
Table 3 Multivariate regression: factors associated with metastases at
staging
Characteristic Odds ratio (95% CI) p
Metastases at staging (PET-CT or laparoscopy)
Age 0.99 (0.96–1.03) 0.582
Gender
Female Reference Reference
Male 0.93 (0.39–2.18) 0.861
Tumor site
Proximal Reference Reference
Body 0.89 (0.31–2.95) 0.823
Distal 0.43 (0.16–1.17) 0.097
Linitis 4.46 (0.92–21.7) 0.064
Lauren classification
Intestinal Reference Reference
Diffuse 0.86 (0.35–2.08) 0.731
T stage
x/1 Reference Reference
2/3 0.95 (0.31–2.88) 0.921
4 1.05 (0.27–4.10) 0.949
N stage
0 Reference Reference
≥ 1 1.39 (0.52–3.69) 0.508
mN
0 Reference Reference
≥ 1 3.92 (1.40–11.0) 0.009
SUVmax 0.94 (0.88–1.02) 0.125
Unsuspected metastases at laparoscopy
Age 1.01 (0.97–1.07) 0.545
Gender
Female Reference Reference
male 0.98 (0.36–2.62) 0.961
Tumor site
Proximal Reference Reference
Body 0.67 (0.19–2.41) 0.543
Distal 0.39 (0.12–1.20) 0.101
Linitis 3.78 (0.64–22.4) 0.143
Lauren classification
Intestinal Reference Reference
Diffuse 0.58 (0.21–1.61) 0.300
T stage
x/1 Reference Reference
2/3 2.25 (0.54–9.33) 0.262
4 11.82 (0.31–10.6) 0.505
N stage
0 Reference Reference
≥ 1 2.57 (0.95–5.42) 0.064
mN
0 Reference Reference
≥ 1 5.19 (1.50–18.0) 0.009
SUVmax 0.96 (0.88–1.04) 0.280
2494 Eur Radiol (2019) 29:2490–2498
Prognosis before treatment
One hundred sixty patients underwent successful surgery (85
after NAC, 75 without). Median OS was 1585 days (IQR
1250, not reached). Median DFS was 1408 days (967–
1849). Median follow-up was 1478 days (1360–1739). On
multivariate Cox regression analysis of pre-treatment factors,
only the presence of FDG-avid nodes at staging was associat-
ed with DFS: HR 2.36 (1.33–4.19; p = 0.003). Prognosis
worsened with mN stage (Table 4; supplementary Table 6).
Prognosis before surgery
Adjusting for NAC, the presence of FDG-avid nodes at staging
remained independent: HR 2.19 (1.23–3.91; p = 0.008). Again,
prognosis worsened with advancing mN stage (Table 4; Fig. 1).
This association was refined when considering those patients
with definitive pre-operative mN stage (n = 75 patients not re-
ceiving NAC, n = 24 patients receiving NAC and restaged by
PET-CT): multivariate HR 2.77 (1.12–6.83; p = 0.027).
Prognosis after surgery
After surgery, a number of pathological factors were associat-
ed with DFS on univariate analysis (supplementary Table 7).
On multivariable analysis, progressive pN and pathological
response (but not mN) remained independent in patients re-
ceiving NAC (supplementary Table 8). In patients not receiv-
ing NAC, no factors were significant.
Predicting DFS before treatment
A recursive partitioning model found FDG-avid nodes to be
the most reliable method of identifying high-risk patients: just
6 of 12 patients (50.0%) were alive and disease-free at 2 years
(0.00% at 5 years), compared with 71/115 (61.7%) without
(23/71; 32.4%; p = 0.002).
Overall, the presence of FDG-avid nodes at staging was high-
ly specific for death/recurrence at 2 years: 92.2% (83.8–97.1),
with a PPVof 66.7% (44.4–83.4). Overall, sensitivity was low:
21.4% (11.6–34.4). At 5 years, specificity rose to 100.0% (85.2–
100), with PPVrising to 72.3% (61.4–81.6). Thiswas identical to
the corresponding logistic regression model.
Association between mN, EUS, and pN
Sixty-one patients were staged with EUS, suggesting nodal
disease in 23 (37.7%). Nine had FDG-avid nodes (all with
EUS-positive nodes). With respect to EUS nodal stage, there
were 9 true positives, no false positives, 14 false negatives,
and 38 true negatives, making the presence of FDG-avid
nodes 39.1% sensitive (19.7–61.4%) and 100% specific
(90.8–100%) for clinical nodal disease at EUS.
Table 4 Multivariate Cox regression analysis before surgery: disease-
free survival
Characteristic HR (95% CI) p
Pre-treatment variables, all patients
T stage
x/1 Reference Reference
2/3 1.88 (0.98–3.60) 0.059
4 1.60 (0.66–3.87) 0.296
mN
0 Reference Reference
1 2.06 (1.05–4.03) 0.035
2 3.48 (1.33–9.12) 0.011
Pre-surgery variables, all patients
T stage
x/1 Reference Reference
2/3 1.67 (0.87–3.22) 0.126
4 1.30 (0.53–3.21) 0.567
mN
0 Reference Reference
1 1.89 (0.96–3.70) 0.065
2 3.44 (1.29–9.22) 0.014
NAC
No Reference Reference
Yes 2.06 (1.25–3.38) 0.004
Pre-surgery variables, patients with definitive pre-operative mN stage
T stage
x/1 Reference Reference
2/3 1.29 (0.54–3.09) 0.564
4 1.20 (0.37–3.95) 0.762
mN
0 Reference Reference
≥ 1 2.77 (1.12–6.83) 0.027
NAC
No Reference Reference
Yes 3.99 (2.08–7.66) < 0.001
Pre-surgery variables, patients with definitive pre-operative mN stage
T stage
x/1 Reference Reference
2/3 1.45 (0.58–3.62) 0.428
4 1.03 (0.30–3.53) 0.996
pN mN
pN0 mN0 Reference Reference
pN1 mN0 2.44 (1.20–4.96) 0.013
pN1 mN1 3.87 (1.35–11.1) 0.012
NAC
No Reference Reference
Yes 3.55 (1.83–6.89) < 0.001
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Of the 99 patients with a definitive pre-operative mN stage,
8 had FDG-avid nodes while 48 had pathologically involved
nodes. All but one of these 8 had pathologically involved
nodes (7 true positives, 1 false positive, 50 true negatives,
and 41 false negatives), making the presence of FDG-avid
nodes 14.6% (6.07–27.8) sensitive and 98.0% (89.6–100.0)
specific for pathologically involved nodes. The single false
negative patient developed early recurrence after 449 days,
raising the possibility of a missed nodal metastasis.
For 98 patients, a hybrid pNmN stage could be generated.
On multivariable analysis (Table 4), relative to pN0mN0 dis-
ease, patients with pN ≥ 1mN0 disease (i.e., non-avid nodal
metastases) had a worse DFS (HR 2.44 [1.20–4.96]; p =
0.013). However, prognosis in those with avid nodal metasta-
ses (pN ≥ 1mN ≥ 1) was even worse (HR 3.87 [1.35–11.1];
p = 0.012; Fig. 1).
Discussion
We found that routinely staging all patients with gastric cancer
with 18F-FDG PET-CT was useful, both identifying unsus-
pected metastases and risk-stratifying patients. In 4.7% of pa-
tients, PET-CT identified unsuspected metastases which
Disease-free survival and mN stage. 
mN0 140 101 73 53 37 23 11 7 5 
mN1 12 9 5 4 2 1 0 0 0 
mN2 8 3 1 0 0 0 0 0 0 
Disease-free survival, pN and mN  
pN0 mN0  49 39 29 24 16 10 3 1 1 
pN1 mN0 41 24 17 12 7 5 2 2 1 





















































Fig. 1 Disease-free survival and
mN stage
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would not have been detected by conventional staging. One
quarter of patients had FDG-avid nodes, which conferred a
worse prognosis: a significantly higher risk of coincident in-
curable disease at staging and worse disease-free survival fol-
lowing surgery if curable (independent of clinical and patho-
logical nodal stage). Utility was not influenced by the Lauren
classification and was supported by decision theory and cost-
effective in a limited economic model.
These findings build on a small number of retrospective
studies. In a 2005 Korean study of 68 patients, Chen et al
reported PET to improve staging by conferring greater sensi-
tivity for identifying resectable metastases [22]; however, this
study excluded patients with diabetes mellitus and performed
PETwithout hybrid CT images and did not demonstrate great-
er sensitivity for distant metastases. Subsequently, Smyth et al
reported selective PET-CT to identify occult metastases in
10% of non-consecutive patients with advanced (T3–4) gas-
tric cancer in the USA, with a similarly favorable cost profile,
although did not assess its utility in patients with less ad-
vanced disease and did not assess nodal avidity [23]. Some
smaller studies have reported the presence of FDG-avid nodes
to confer a worse prognosis, although in less defined cohorts.
In 151 patients undergoing gastrectomy in Korea, Song et al
found those with resectable FDG-avid nodes (SUVmax > 2.8)
to have worse OS and DFS [8], although did not quantify mN
stage. Moreover, this study assessed only patients with nodal
involvement pathologically following surgery, by definition
not assessing the utility of PET-CT in detecting metastases,
and also excluding patients receiving NAC (the majority in
clinical practice). In 2016, Wang et al assessed the latter in 50
patients in China, finding those with mN stage 2 had worse
OS, but notably included patients undergoing non-curative
surgery [9]. Coupe et al previously reported FDG-avid nodes
to confer a worse prognosis in 68 patients with GOJ or gastric
cancer, although did not assess the staging utility of PET-CT
and also included patients undergoing non-curative treatment
[24]. However, we believe ours to be the largest study to date,
the first in a primarily Caucasian population of non-junctional
cancer and also the first to demonstrate associations between
avid nodes and metastatic disease. The latter suggests a mech-
anism by which FDG-avid nodes confer a worse prognosis, as
a surrogate for a more aggressive and metastatic cancer phe-
notype. This is illustrated by the relative insensitivity but ab-
solute specificity of PET-CTas regards nodal disease, suggest-
ing the merit of PET-CT to be the identification of a subset of
patients with nodal metastases with worse disease.
If validated, these novel findings have a number of impli-
cations. Firstly, they suggest that a sizable minority of patients
when not staged by PET-CT have detectable metastatic dis-
ease and undergo futile radical therapy. Routine use of PET-
CT might allow these patients to commence palliative thera-
pies sooner and obviate the risks, complications, trauma, and
costs of well-intentioned but ultimately futile treatment.
Secondly, routine PET-CT may identify metastatic disease
rendering laparoscopy and EUS unnecessary, similarly obvi-
ating their risks and costs (although both retain invaluable
roles in patients without metastases evident on PET-CT).
Thirdly, patients with FDG-avid nodes at staging may have
a more aggressive phenotype.
This is independent of the mere presence of nodal metas-
tases, suggesting FDG avidity is a useful surrogate biomarker.
Such high-risk patients might be targeted for more intensive
staging and restaging investigations. Finally, these patients
(particularly those with a definitive mN stage before surgery)
can be counseled more fully as to their prognosis, allowing
them to make more informed decisions and undergo tailored
surveillance.
These findings also highlight priorities for research. Our
cohort was insufficient to determine whether restaging pa-
tients with PET-CT rather than CT is preferable, but intuitively
the greater sensitivity of PET-CT should translate to restaging
(as we previously reported in esophageal cancer) [13]. It is
also unclear whether PET-CTmay have similar utility in mon-
itoring response of nodal metastases to NAC [6]. While we
did not find mN stage to be an independent marker of prog-
nosis once adjusting for pathological stage, this might be due
to the limited number of patients with a definitive pre-
operative mN stage.
We acknowledge our study to have a number of limitations
and sources of bias; these include its retrospective nature—
although by performing PET-CT routinely, we believe the
potential for selection bias is minimal, and the results gener-
alizable, although we acknowledge potential bias in the use of
PET-CT to corroborate suspicious but equivocal metastases
on prior CT; a study period spanning evolution in technology
and clinical practice potentially introducing performance bias,
as well as the need to consider cT2 and cT3 diseases as a
single variable and its single-center nature. Consequently, pro-
spective and external validationwill be required. Our econom-
ic modeling was by necessity limited and conservative. We
chose the UK NHS tariffs as a consistent and pragmatic esti-
mate of costs; in reality, once additive costs are included, and
most importantly those financial, physical and psychological
costs incurred by patients and those supporting them, it is
likely that the net savings of will be far greater. Beyond this,
as our primary aim was to assess staging utility, we have
included a number of patients with limited follow-up, with
resultant detection bias and performance bias for prognostica-
tion. Also, by performing on-demand investigations for recur-
rence tailored to symptoms, it is again likely that some in-
stances of recurrence in these patients are yet to be detected.
In summary, we found routine staging PET-CT to identify
metastases in 7% of patient with non-junctional cancer, most
of which would not be identified by conventional staging.
This prevented patients receiving futile radical therapy, and
its routine use was supported both by decision theory and
Eur Radiol (2019) 29:2490–2498 2497
limited economic modeling. Furthermore, PET-CT identifies
patients with avid nodes who are at substantially higher risk of
metastatic disease and a worse prognosis following radical
treatment. mN stage therefore appears to be a novel and useful
biomarker when staging non-junctional gastric cancer.
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